- Home
- IOBT vs MURA Comparison
IOBT vs MURA Comparison
Compare IOBT & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- MURA
- Stock Information
- Founded
- IOBT 2014
- MURA 2013
- Country
- IOBT Denmark
- MURA Ireland
- Employees
- IOBT N/A
- MURA N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- MURA
- Sector
- IOBT Health Care
- MURA
- Exchange
- IOBT Nasdaq
- MURA Nasdaq
- Market Cap
- IOBT 56.7M
- MURA 57.2M
- IPO Year
- IOBT 2021
- MURA N/A
- Fundamental
- Price
- IOBT $0.77
- MURA $3.20
- Analyst Decision
- IOBT Strong Buy
- MURA Strong Buy
- Analyst Count
- IOBT 3
- MURA 4
- Target Price
- IOBT $9.33
- MURA $16.00
- AVG Volume (30 Days)
- IOBT 629.4K
- MURA 270.3K
- Earning Date
- IOBT 11-12-2024
- MURA 11-13-2024
- Dividend Yield
- IOBT N/A
- MURA N/A
- EPS Growth
- IOBT N/A
- MURA N/A
- EPS
- IOBT N/A
- MURA N/A
- Revenue
- IOBT N/A
- MURA N/A
- Revenue This Year
- IOBT N/A
- MURA N/A
- Revenue Next Year
- IOBT N/A
- MURA N/A
- P/E Ratio
- IOBT N/A
- MURA N/A
- Revenue Growth
- IOBT N/A
- MURA N/A
- 52 Week Low
- IOBT $0.66
- MURA $2.88
- 52 Week High
- IOBT $2.10
- MURA $6.25
- Technical
- Relative Strength Index (RSI)
- IOBT 38.48
- MURA 32.85
- Support Level
- IOBT $0.75
- MURA $3.50
- Resistance Level
- IOBT $0.84
- MURA $4.20
- Average True Range (ATR)
- IOBT 0.07
- MURA 0.25
- MACD
- IOBT 0.00
- MURA -0.09
- Stochastic Oscillator
- IOBT 16.90
- MURA 1.96
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.